Immune Responses After Human Subject Challenge With Sand Fly Bites
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01289977|
Recruitment Status : Completed
First Posted : February 4, 2011
Last Update Posted : February 19, 2018
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||68 participants|
|Official Title:||Immune Responses After Human Subject Challenge With Sand Fly Bites: Exploratory Study for Selection of Potential Leishmania Vaccine Antigen Candidates|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 15, 2016|
Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
Those placed in this group will receive exposure to L. longipalpis sand fly bites.
- Human Th1 immune response to specific sand fly salivary proteins [ Time Frame: 6-18 months ]Subject blood will be obtained at set points after repeated controlled sand fly feedings, duration for 20 minutes. Sand fly salivary molecules that demonstrate a strong Th1 immune response in these human PBMC, and little Th2 cytokine induction will be considered for development as future leishmania vaccine antigen candidates.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01289977
|United States, Maryland|
|Walter Reed National Military Medical Center|
|Bethesda, Maryland, United States, 20814|
|Principal Investigator:||Naomi E Aronson, MD||Uniformed Services University of the Health Sciences|